Drug Type Autologous CAR-T |
Synonyms- |
Target |
Mechanism CEA inhibitors(Carcinoembryonic antigen inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 07 Jun 2022 | |
Colonic Cancer | Phase 2 | CN | 07 Jun 2022 | |
Esophageal Carcinoma | Phase 2 | CN | 07 Jun 2022 | |
Rectal Cancer | Phase 2 | CN | 07 Jun 2022 | |
Breast Cancer | Phase 2 | CN | 20 Feb 2020 | |
Lung Cancer | Phase 2 | CN | 20 Feb 2020 | |
Pancreatic Cancer | Phase 2 | CN | 20 Feb 2020 | |
Stomach Cancer | Phase 2 | CN | 20 Feb 2020 | |
Recurrent Carcinoma | Preclinical | CN | 20 Feb 2020 | |
Liver Cancer | Discovery | CN | 20 Feb 2020 |
NCT05396300 (ASCO2024) Manual | Phase 1 | Solid tumor Third line | 40 | (intravenous) | (ggprydxwsh) = pppedlrxbf ulfbzmehxh (vrodbwaolq ) View more | Positive | 24 May 2024 |
(intravenous + Low Dose) | (ggprydxwsh) = xwcteqdepe ulfbzmehxh (vrodbwaolq ) View more |